Antidepressant efficacy and side effect burden: an updated guide for clinicians
Antidepressant treatment has been evolving and changing since the 1950s following the discovery of the classic antidepressant treatments including tricyclic antidepressants and monoamine oxidase inhibitors. The heterogeneity of the disorder became apparent in the beginning when individuals remained...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BioExcel Publishing Ltd
2020-05-01
|
Series: | Drugs in Context |
Subjects: | |
Online Access: | https://www.drugsincontext.com/antidepressant-efficacy-and-side-effect-burden:-an-updated-guide-for-clinicians |
id |
doaj-3bd0c73a1f2342309e7678dea24b0afc |
---|---|
record_format |
Article |
spelling |
doaj-3bd0c73a1f2342309e7678dea24b0afc2020-11-25T03:04:10ZengBioExcel Publishing LtdDrugs in Context1740-43981740-43982020-05-01911110.7573/dic.2020-2-2Antidepressant efficacy and side effect burden: an updated guide for cliniciansTatum KutzerMichelle DickTrevor ScudamoreMark WienerThomas SchwartzAntidepressant treatment has been evolving and changing since the 1950s following the discovery of the classic antidepressant treatments including tricyclic antidepressants and monoamine oxidase inhibitors. The heterogeneity of the disorder became apparent in the beginning when individuals remained symptomatic despite medication compliance. This spurred further research in order to understand the neurobiology underlying the disorder. Subsequently, newer medications were designed to target specific neurotransmitters and areas of the brain involved in symptom development and maintenance. Our original review article looked at both classic and modern antidepressant medications used in the treatment of major depressive disorder. This manuscript is an update to the original review and serves to provide clinicians with information about novel antidepressant medications, augmentation strategies with atypical antipsychotics, over-the-counter medications, as well as nonpharmaceutical treatments that should be considered when treating each individual patient who remains symptomatic despite treatment effortshttps://www.drugsincontext.com/antidepressant-efficacy-and-side-effect-burden:-an-updated-guide-for-cliniciansantidepressantsantipsychoticsdepressionmajor depressive disorderneuromodulatorpostpartum depressiontherapeutictreatment-resistant depression |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Tatum Kutzer Michelle Dick Trevor Scudamore Mark Wiener Thomas Schwartz |
spellingShingle |
Tatum Kutzer Michelle Dick Trevor Scudamore Mark Wiener Thomas Schwartz Antidepressant efficacy and side effect burden: an updated guide for clinicians Drugs in Context antidepressants antipsychotics depression major depressive disorder neuromodulator postpartum depression therapeutic treatment-resistant depression |
author_facet |
Tatum Kutzer Michelle Dick Trevor Scudamore Mark Wiener Thomas Schwartz |
author_sort |
Tatum Kutzer |
title |
Antidepressant efficacy and side effect burden: an updated guide for clinicians |
title_short |
Antidepressant efficacy and side effect burden: an updated guide for clinicians |
title_full |
Antidepressant efficacy and side effect burden: an updated guide for clinicians |
title_fullStr |
Antidepressant efficacy and side effect burden: an updated guide for clinicians |
title_full_unstemmed |
Antidepressant efficacy and side effect burden: an updated guide for clinicians |
title_sort |
antidepressant efficacy and side effect burden: an updated guide for clinicians |
publisher |
BioExcel Publishing Ltd |
series |
Drugs in Context |
issn |
1740-4398 1740-4398 |
publishDate |
2020-05-01 |
description |
Antidepressant treatment has been evolving and changing since the 1950s following the discovery of the classic antidepressant treatments including tricyclic antidepressants and monoamine oxidase inhibitors. The heterogeneity of the disorder became apparent in the beginning when individuals remained symptomatic despite medication compliance. This spurred further research in order to understand the neurobiology underlying the disorder. Subsequently, newer medications were designed to target specific neurotransmitters and areas of the brain involved in symptom development and maintenance. Our original review article looked at both classic and modern antidepressant medications used in the treatment of major depressive disorder. This manuscript is an update to the original review and serves to provide clinicians with information about novel antidepressant medications, augmentation strategies with atypical antipsychotics, over-the-counter medications, as well as nonpharmaceutical treatments that should be considered when treating each individual patient who remains symptomatic despite treatment efforts |
topic |
antidepressants antipsychotics depression major depressive disorder neuromodulator postpartum depression therapeutic treatment-resistant depression |
url |
https://www.drugsincontext.com/antidepressant-efficacy-and-side-effect-burden:-an-updated-guide-for-clinicians |
work_keys_str_mv |
AT tatumkutzer antidepressantefficacyandsideeffectburdenanupdatedguideforclinicians AT michelledick antidepressantefficacyandsideeffectburdenanupdatedguideforclinicians AT trevorscudamore antidepressantefficacyandsideeffectburdenanupdatedguideforclinicians AT markwiener antidepressantefficacyandsideeffectburdenanupdatedguideforclinicians AT thomasschwartz antidepressantefficacyandsideeffectburdenanupdatedguideforclinicians |
_version_ |
1724682542485864448 |